1.
IMNM不同抗体组临床特征的比较
Comparisons of clinical features of different serological subgroups of IMNM
| Features | IMNM(n=104) | Anti-SRP(n=47) | Anti-HMGCR(n=23) | MSAs negative(n=34) | P |
| ILD, interstitial lung diseases; CTD, connective tissue diseases; IMNM, immune mediated necrotizing myopathies; SRP, signal recognition particle; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MSAs, myositis specific autoantibodies. Data are shown as n(%) and x±s. * P<0.017, between anti-HMGCR group and anti-SRP /MSAs negative group; # P<0.017, between anti-SRP and anti-HMGCR/MSAs negative group; △ P<0.017, between MSAs negative and anti-SRP/anti-HMGCR group. | |||||
| Female | 73 (70.2) | 38 (80.9) | 13 (56.5) | 22 (64.7) | 0.078 |
| Age/years | 46.24±15.38 | 47.49±15.76 | 46.09±18.08 | 44.62±12.02 | 0.712 |
| Age of onset/years | 44.63±16.03 | 46.11±16.21 | 44.13±20.83 | 42.91±11.82 | 0.671 |
| Duration/months | 20.85±27.79 | 19.01±25.08 | 25.5±35.03 | 10.23±26.36 | 0.652 |
| Chronic progression (>12 months) | 59 (56.7) | 28 (59.6) | 12 (52.2) | 19 (55.9) | 0.836 |
| Fever | 5 (4.8) | 3 (6.4) | 1 (4.3) | 1 (2.9) | 0.763 |
| Loss of weight | 31 (29.8) | 14 (29.8) | 4 (17.1) | 13 (32.8) | 0.241 |
| Muscle weakness | 96 (92.3) | 44 (93.6) | 21 (91.3) | 31 (91.1) | 0.902 |
| Severe muscle weakness | 48 (46.2) | 22 (46.8) | 9 (39.1) | 17 (50.0) | 0.716 |
| Muscle atrophy | 15/73(20.5) | 5/33 (15.6) | 4/17 (23.5) | 6/24 (25.0) | 0.651 |
| Myalgia | 29 (27.9) | 13 (27.7) | 8 (34.8) | 8 (23.5) | 0.649 |
| Arthritis | 10 (9.6) | 4 (8.5) | 1 (4.3) | 5 (14.7) | 0.404 |
| Skin involvement | 27 (26.0) | 12 (25.5) | 8 (34.8) | 7 (20.6) | 0.485 |
| Heliotrope rash | 7 (7.7) | 3 (6.4) | 2 (8.7) | 3 (8.8) | 0.902 |
| Gottron’s sign | 2 (1.9) | 1 (2.1) | 0 | 1 (2.9) | 0.723 |
| “V” sign | 11 (10.6) | 2 (4.3) | 7 (30.4) | 2 (5.9) | 0.002* |
| Shawl sign | 6 (5.8) | 2 (4.3) | 4 (17.4) | 0 | 0.018 |
| Raynaud phenomenon | 4 (3.8) | 3 (6.4) | 0 | 1 (2.9) | 0.404 |
| ILD | 46/99 (46.5) | 29/45 (64.4) | 7/23 (30.4) | 10/31 (29.0) | 0.004# |
| Cough | 2/46 (4.3) | 2/29 (6.9) | 0/7 | 0/10 | 0.542 |
| Dyspnea | 4/46 (8.7) | 3/29 (10.3) | 0/7 | 1/10 (10.0) | 0.675 |
| Asymptomatic | 41/46 (89.1) | 25/29 (86.2) | 7/7 (100.0) | 9/10 (90.0) | 0.572 |
| Dysphagia | 35 (33.7) | 17 (36.2) | 8 (34.8) | 10 (29.4) | 0.576 |
| Cancer | 4 (3.8) | 3 (6.4) | 1 (4.3) | 0 | 0.334 |
| With other CTD | 16 (15.4) | 4 (8.5) | 1 (4.3) | 11 (32.4) | 0.003△ |
| Death | 5 (4.8) | 3 (6.4) | 1 (4.3) | 1 (2.9) | 0.769 |